|
Year:
2021 |
Month:
July
|
Volume:
10 |
Issue:
3 |
Page:
PO70 - PO72 |
Association of Neutrophil Lymphocyte Ratio and Glycaemic Control in Patients with Type 2 Diabetes Mellitus
|
|
Correspondence
Pranathi Mahankali, Sruthi Nannapaneni, Kalyan Chakravarthy Vallabhaneni, Naveen Chandra Rao Damera, Rangarao Diddi, Sruthi Nannapaneni,
Nannapaneni Street, Ithanagr, Tenali, Guntur, Andhra Pradesh, India.
E-mail: drshruti2511@gmail.com
:
|
|
Introduction: Neutrophil-Lymphocyte Ratio (NLR) is an easily measurable novel marker of systemic inflammation and is related to cardiovascular disease in patients with type 2 diabetes mellitus. Glycated haemoglobin A (HbA1c) levels are an indicator of blood glucose regulation. However, HbA1c usually do not predict diabetes associated complications accurately.
Aim: To measure NLR and HbA1c values and to determine their association in patients with type 2 diabetes mellitus.
Materials and Methods: This observational analytical study was conducted in a tertiary care centre. Data was collected over a period of six months from June 2020 to December 2020. 100 random patients diagnosed with type 2 diabetes mellitus according to American Diabetes Association (ADA) criteria were included in the study. Patients were divided into two groups, group A with HbA1c ≤7 (regulated diabetes) and group B with >7 HbA1c (unregulated diabetes).
Results: Using independent t-test, the NLR ratios were found to be significantly higher in group B when compared to group A (2.41±0.11 verses 1.31±0.57, respectively). Mean HbA1c (%) levels were 6.67±0.14 and 8.79±0.21 in groups A and B, respectively. Linear regression analysis showed that NLR correlated positively with HbA1c with a p-value <0.001.
Conclusion: NLR is an easily available, safe, cost-effective and a simple test. It can also guide the physician in resource limited settings like Primary Health Centres (PHC) to evaluate a patient with type 2 diabetes for microvascular and macrovascular complications. So, it can be used as a disease monitoring tool during the follow-up of diabetics.
|
|
[ FULL
TEXT ] | [ ]
|
|
Print
|
|